This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Genetics

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The mode of inheritance of familial hypertrophic cardiomyopathy is typically autosomal dominant with incomplete penetrance.

Linkage analysis has shown that the genetics of hypertrophic cardiomyopathy is heterogenous with four clear loci involved:

  • beta myosin heavy chain on chromosome 14 (30% of cases)
  • alpha-tropomyosin on chromosome 15 (3% of cases)
  • cardiac troponin T on chromosome 1 (15% of cases)
  • a locus on chromosome 11

There is no good correlation with the degree of myocardial hypertrophy and the risk of sudden cardiac death. Conversely there may be a good correlation between specific mutations and the risk of sudden death e.g. the Ile79Asn mutation in troponin T results in mild hypertrophy but a high risk of sudden death.

DNA screening in this disease remains complex, time consuming, mainly confined to a few research laboratories, and is not part of routine clinical evaluation.At present, genetic screening identifies the mutation in 50-60% of patients (1).

Reference:

  1. BMJ 2006;332:1251-1255.
  2. Oakley, C. Heart muscle disease. Medicine International 1993; 21(11):421-6.
  3. Watkins, H. et al. Mutations in the genes for troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. New Engl J Med. 1995; 332:1058

 


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.